BCAL Diagnostics (ASX:BDX) Interest Expense : A$-0.07 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BCAL Diagnostics's interest expense for the six months ended in Dec. 2023 was A$ -0.05 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.07 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BCAL Diagnostics's Operating Income for the six months ended in Dec. 2023 was A$ -4.22 Mil. BCAL Diagnostics's Interest Expense for the six months ended in Dec. 2023 was A$ -0.05 Mil. BCAL Diagnostics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BCAL Diagnostics Interest Expense Historical Data

The historical data trend for BCAL Diagnostics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Interest Expense Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

Interest Expense

-0.02

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial			-	-	-	-0.02	-0.05

BCAL Diagnostics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.07 Mil.

BCAL Diagnostics (ASX:BDX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BCAL Diagnostics's Interest Expense for the six months ended in Dec. 2023 was A$-0.05 Mil. Its Operating Income for the six months ended in Dec. 2023 was A$-4.22 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was A$1.14 Mil.

BCAL Diagnostics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

BCAL Diagnostics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.